Clinigen Group, a global specialty pharmaceutical products and pharma services business, has been named the fastest-growing private company in the UK.
The Sunday Times Virgin Fast Track 100 league table, published today, ranks 100 UK-based firms according to their sales growth over the past three years. Fast Track has a strong track record of identifying innovative entrepreneurial ventures that have gone on to become successful national and global businesses. Companies listed in the past include ARM Holdings, Carphone Warehouse, Innocent and Jack Wills.
"Our position at the top of the Fast Track 100 league table reflects robust organic growth in our original business lines, as well as the addition of Keats Healthcare in 2010," said group chief executive officer Peter George. "All our businesses are aligned with Clinigen´s mission to get the right drug to the right patient at the right time, whether that´s in a clinical trial, a discontinued treatment, or for an individual patient need."
Clinigen Group has achieved 242% year-on-year growth, rising from an annualised £875,000 in 2008 to £35 million in the financial year ended June 2011.
Through its Healthcare Division, Clinigen acquires and in-licenses from the top 50 pharmaceutical companies mature or end-of-lifecycle drugs which have been targeted for discontinuation or withdrawal. Clinigen provides companies with an attractive option for divesting non-core assets while ensuring an uninterrupted supply of products for patients and physicians. Clinigen also looks to drive sales growth from the drugs it acquires.
"Our presence and key networks in virtually all of the world´s major markets make Clinigen a partner of choice for big pharmaceutical companies wanting to divest mature assets," commented Anton Jenkins, chief operating officer of Clinigen Healthcare.
In March 2010, Clinigen acquired from AstraZeneca exclusive rights to the antiviral Foscavir in all global markets. Clinigen holds marketing authorisations to sell Foscavir as a treatment for HIV/AIDS-related cytomegalovirus infections and herpes in 16 markets, as well as in bone marrow transplantation in Japan. Clinigen aims to secure licences to market Foscavir in additional markets, including the US in Q1 2012. Sales of Foscavir grew from £1.5 million last year to £9.7 million in 2011 and are expected to reach £20.5 million in 2015.
About Clinigen
Clinigen Group is a specialty pharmaceutical and pharma services company formed by merger in 2010. Clinigen Healthcare acquires or in-licenses mature or end-of-lifecycle drugs for development and commercialisation in hospitals. Core therapeutic areas include oncology, leukaemia, haematology, transplantation, virology, pain management and critical care. The company also looks to acquire products in orphan indications.
Keats Healthcare (Clinigen CTS) works in partnership with a network of suppliers, sourcing commercial medicinal products for exclusive use in customers´ clinical studies.
Clinigen GAP´s global access programmes help to ensure markets are supported and supplied while customers´ products go through the regulatory and launch process. They also support the withdrawal or discontinuation of pharma companies´ end-of-lifecycle medicines.
Clinigen Group is headquartered in Burton-on-Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan. Visit: www.clinigengroup.com.
About Foscavir
Foscavir (foscarnet sodium) is licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients in Australia, Belgium, France, Germany, Hungary, Israel, Italy, Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Singapore, Spain, Switzerland and the UK. In July 2011, Foscavir was approved in Japan to treat CMV in hematopoietic stem cell transplant patients.
